+

WO1999063992A8 - Nouveaux medicaments pour traiter les etats dus aux canaux calcium et leurs utilisations - Google Patents

Nouveaux medicaments pour traiter les etats dus aux canaux calcium et leurs utilisations

Info

Publication number
WO1999063992A8
WO1999063992A8 PCT/US1999/012672 US9912672W WO9963992A8 WO 1999063992 A8 WO1999063992 A8 WO 1999063992A8 US 9912672 W US9912672 W US 9912672W WO 9963992 A8 WO9963992 A8 WO 9963992A8
Authority
WO
WIPO (PCT)
Prior art keywords
calcium channel
novel calcium
channel drugs
drugs
novel
Prior art date
Application number
PCT/US1999/012672
Other languages
English (en)
Other versions
WO1999063992A1 (fr
WO1999063992A9 (fr
Inventor
Yu-Hua Ji
Maya Natarajan
John H Griffin
Original Assignee
Advanced Medicine Inc
Ji Yu Hua
Maya Natarajan
John H Griffin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc, Ji Yu Hua, Maya Natarajan, John H Griffin filed Critical Advanced Medicine Inc
Priority to EP99928427A priority Critical patent/EP1085863A1/fr
Priority to CA002318901A priority patent/CA2318901A1/fr
Priority to JP2000553061A priority patent/JP2002517440A/ja
Priority to AU45493/99A priority patent/AU4549399A/en
Publication of WO1999063992A1 publication Critical patent/WO1999063992A1/fr
Publication of WO1999063992A8 publication Critical patent/WO1999063992A8/fr
Publication of WO1999063992A9 publication Critical patent/WO1999063992A9/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

L'invention concerne de nouveaux composés à liaisons multiples comprenant 2 à 10 ligands fixés par covalence, chacun de ces ligands étant capable de se lier à un site de liaison de ligand dans un canal Ca++ pour moduler les activités biologiques de ce canal.
PCT/US1999/012672 1998-06-08 1999-06-07 Nouveaux medicaments pour traiter les etats dus aux canaux calcium et leurs utilisations WO1999063992A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99928427A EP1085863A1 (fr) 1998-06-08 1999-06-07 Nouveaux medicaments pour traiter les etats dus aux canaux calcium et leurs utilisations
CA002318901A CA2318901A1 (fr) 1998-06-08 1999-06-07 Nouveaux medicaments pour traiter les etats dus aux canaux calcium et leurs utilisations
JP2000553061A JP2002517440A (ja) 1998-06-08 1999-06-07 新規カルシウムチャンネル薬物および用途
AU45493/99A AU4549399A (en) 1998-06-08 1999-06-07 Novel calcium channel drugs and uses

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8846598P 1998-06-08 1998-06-08
US60/088,465 1998-06-08
US9306898P 1998-07-16 1998-07-16
US60/093,068 1998-07-16
US10386698P 1998-10-12 1998-10-12
US60/103,866 1998-10-12

Publications (3)

Publication Number Publication Date
WO1999063992A1 WO1999063992A1 (fr) 1999-12-16
WO1999063992A8 true WO1999063992A8 (fr) 2001-02-22
WO1999063992A9 WO1999063992A9 (fr) 2002-08-22

Family

ID=27375969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/012672 WO1999063992A1 (fr) 1998-06-08 1999-06-07 Nouveaux medicaments pour traiter les etats dus aux canaux calcium et leurs utilisations

Country Status (7)

Country Link
EP (1) EP1085863A1 (fr)
JP (1) JP2002517440A (fr)
AR (1) AR020876A1 (fr)
AU (1) AU4549399A (fr)
CA (1) CA2318901A1 (fr)
SG (1) SG80038A1 (fr)
WO (1) WO1999063992A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101909B2 (en) 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
DK1628663T3 (da) 2003-05-15 2010-03-08 Roskamp Res Llc Fremgangsmåde til fremstilling af medikamenter til reduktion af amyloid-aflejring, amyloid-neurotoksicitet og mikrogliose
NZ584729A (en) 2007-10-05 2012-12-21 Alzheimer S Inst Of America Inc Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042769A1 (de) * 1980-11-13 1982-06-09 Bayer Ag, 5090 Leverkusen C-3 verknuepfte 1,4-dihydropyridine, ihre verwendung in arzneimitteln und verfahren zu ihrer herstellung
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
US4771057A (en) * 1986-02-03 1988-09-13 University Of Alberta Reduced pyridyl derivatives with cardiovascular regulating properties
EP0510132B1 (fr) * 1990-09-28 1997-05-14 Neorx Corporation Porteurs polymeres servant a la liberation d'agents a liaison covalente
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
WO1996033972A1 (fr) * 1995-04-28 1996-10-31 Glaxo Group Limited Procedes de synthese de divers ensembles de pyridines, pyrimidines, derives 1,4-dihydro de ces composes et derives de piperidine
NZ280378A (en) * 1995-11-01 1998-04-27 Apotex Inc 4-phenyl-1,4-dihydropyridine-3,5-dicarboxylic acid compounds, preparation, intermediate compounds
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6403305B1 (en) * 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor

Also Published As

Publication number Publication date
JP2002517440A (ja) 2002-06-18
AU4549399A (en) 1999-12-30
WO1999063992A1 (fr) 1999-12-16
EP1085863A4 (fr) 2001-03-28
EP1085863A1 (fr) 2001-03-28
SG80038A1 (en) 2001-04-17
CA2318901A1 (fr) 1999-12-16
AR020876A1 (es) 2002-06-05
WO1999063992A9 (fr) 2002-08-22

Similar Documents

Publication Publication Date Title
ZA9710098B (en) Halogenopyrimidines.
WO2004075865A3 (fr) Modulation selective d'une activite biologique induite par le recepteur tlr
AU2508499A (en) Ligands of the cd47 antigen, agents binding the ligands of the cd47 antigen and uses thereof
WO2005077981A3 (fr) Polypeptides fc a nouveaux sites de liaison de ligands fc
WO1999063944A3 (fr) Nouveaux agents therapeutiques modulant les recepteurs des oestrogenes
WO2001068142A9 (fr) Systemes de ligands therapeutiques et diagnostiques pouvant lier une molecule porteuse et medicaments contenant ces ligands
WO1999011791A3 (fr) Recepteurs et ligands de la famille du facteur de necrose tumorale, acides nucleiques codants et agents de liaison associes
DE69634909D1 (de) Mit lumineszierenden Lanthanidchelaten markierte, biospezifisch bindende Reaktanden und ihre Verwendung
WO2003050295A3 (fr) Essais et mises en oeuvre permettant de determiner et de moduler une activite de liaison hsp90
IS5888A (is) Efnameðferð við krabbameini með asetýldínalíni blönduðu gemsítabíni, kapesítabíni eða sisplatíni
HUP9901874A3 (en) Human antibodies binding human tnfalfa, pharmaceutical compositions containing thereof and use thereof
DE69802615D1 (de) Triaromatische Verbindungen, diese enthaltende Zusammensetzungen sowie ihre Anwendungen
DE69807435D1 (de) Mischer zum Mischen von Lacken, Farbstoffen od. dgl.
AU2682499A (en) Anion binding polymers and the use thereof
WO1999032509A3 (fr) Analogues d'hemiasterline
AU1974100A (en) 4-trifluoromethyl-3-oxadiazolyl pyridines, methods for the production thereof, agents containing these compounds, and their use as pesticides
DK1049721T3 (da) Syntetiske polysaccharider, fremgangsmåde til fremstilling heraf og farmaceutiske præparater indeholdende disse
WO1999064040A8 (fr) Nouveaux composes de macrolides de polyene et leurs utilisations
WO1999063992A8 (fr) Nouveaux medicaments pour traiter les etats dus aux canaux calcium et leurs utilisations
WO2001012664A3 (fr) Ligands recepteurs du gene notch, et utilisations associees
AU3602695A (en) Novel n3s2 chelating ligands optionally radiolabelled with tc or re, useful for diagnostic or therapeutic applications
AU2001291771A1 (en) Cycloaliphatic/aromatic diphosphines and use thereof in catalysis
AU1724300A (en) Calcium binding protein
AU4118397A (en) Substituted 2-phenylpyridine as herbicide
AU6093298A (en) Adhesive-containing pesticides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999928427

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase in:

Ref document number: 2318901

Country of ref document: CA

Ref country code: CA

Ref document number: 2318901

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 505978

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 45493/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000/04563

Country of ref document: ZA

Ref document number: 200004563

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 09674422

Country of ref document: US

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 553061

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWP Wipo information: published in national office

Ref document number: 1999928427

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 61-66 AND 126-131, DESCRIPTION, REPLACED BY NEW PAGES 61A-66 AND 126-131; PAGES 1/20-20/20, DRAWINGS, REPLACED BY NEW PAGES 1/25-25/25; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 1999928427

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载